- MRNA +3.49%
Moderna’s Laval facility gains Health Canada’s drug establishment licence
Yahoo Finance · 1 day ago
Open | 76.15 |
High | 79.96 |
Low | 75.95 |
Mkt Cap | 30.47B |
P/E (TTM) | N/A |
Div & Yield | N/A & N/A |
Prev. Close | 76.61 |
52 Wk. Low | 62.55 |
52 Wk. High | 170.47 |
Related stocks
American biotechnology company
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. Wikipedia
(USD) | Q2 2024 | Y/Y |
---|---|---|
Revenue | 241M | 29.90% ▼ |
Net Income | -1.28B | - |
Diluted EPS | -3.33 | - |
Quarter | EPS Estimate | EPS Actual |
---|---|---|
Q3 2024 | -$1.70 | - |
Q2 2024 | -$3.38 | -$3.33 |
Q1 2024 | -$3.58 | -$3.07 |
S&P FuturesES=F | 5,501.75-2.25 (-0.04%) |
Dow FuturesYM=F | 40,667.00-131.00 (-0.32%) |
Nasdaq FuturesNQ=F | 18,891.25+27.25 (+0.14%) |
18.63+3.27% | |
1.3300+306.60% | |
205.56-5.19% |